COMPASS Pathways (DE:5Y6)
FRANKFURT:5Y6
5Y6 Stock Chart & Stats
€5.25
-€0.46(-9.79%)
At close: 4:00 PM EST
€5.25
-€0.46(-9.79%)
Day’s Range― - ―
52-Week Range€2.10 - €7.65
Previous CloseN/A
Volume0.00
Average Volume (3M)95.00
Market Cap
€482.92M
Enterprise Value€441.76M
Total Cash (Recent Filing)€149.61M
Total Debt (Recent Filing)€35.03M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
May 07, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding128,923,300
10 Day Avg. Volume15
30 Day Avg. Volume95
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-12.21
Price to Sales (P/S)0.00
P/FCF Ratio-4.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€18.82Price Target Upside258.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.48
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And DurabilityPhase 3 trials met primary endpoints with reproducible outcomes across single- and multi-dose studies, and durable symptom improvements including strengthened response after a second dose support a differentiated clinical profile.
Commercial Readiness And ReimbursementRecent financing extended the cash runway and strategic partnerships, together with new reimbursement codes for hourly monitoring, improve the economic case and operational readiness for commercialization.
Regulatory PathwayAnalysts note that a Type A meeting with the FDA and a nearly complete rolling submission, with a final dataset remaining, clarify the approval pathway and reduce regulatory uncertainty.
Bears Say
Financial SustainabilitySubstantial operating losses alongside rising research and general expenses increase pressure on financial resources and could require additional financing that dilutes existing investors or slows development plans.
Regulatory Interpretation RiskSmaller-than-expected effect sizes and indications that a low-dose control had active effects could complicate trial interpretation and create additional regulatory hurdles.
Scalability Of Treatment ModelThe lengthy inpatient treatment session and intensive monitoring required for administration may constrain clinic capacity and make broad commercial rollout difficult to scale.
COMPASS Pathways News
5Y6 FAQ
What was COMPASS Pathways’s price range in the past 12 months?
COMPASS Pathways lowest stock price was €2.10 and its highest was €7.65 in the past 12 months.
What is COMPASS Pathways’s market cap?
COMPASS Pathways’s market cap is €482.92M.
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is May 07, 2026 which is in 32 days.
How were COMPASS Pathways’s earnings last quarter?
COMPASS Pathways released its earnings results on Mar 24, 2026. The company reported -€0.868 earnings per share for the quarter, missing the consensus estimate of -€0.35 by -€0.518.
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate is -0.37.
How many shares outstanding does COMPASS Pathways have?
COMPASS Pathways has 128,923,300 shares outstanding.
What happened to COMPASS Pathways’s price movement after its last earnings report?
COMPASS Pathways reported an EPS of -€0.868 in its last earnings report, missing expectations of -€0.35. Following the earnings report the stock price went down -3.982%.
Which hedge fund is a major shareholder of COMPASS Pathways?
Currently, no hedge funds are holding shares in DE:5Y6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
COMPASS Pathways Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€18.82 (258.53% Upside)
€18.82 (258.53% Upside)
Blogger Sentiment
Neutral
DE:5Y6 Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.37%
12-Months-Change
Fundamentals
Return on Equity
-335.93%
Trailing 12-Months
Asset Growth
-1.55%
Trailing 12-Months
Company Description
COMPASS Pathways
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
5Y6 Stock 12 Month Forecast
Average Price Target
€18.82
▲(258.53% Upside)
Technical Analysis
Cross Country Healthcare
―
Oncology Institute
―
Talkspace
―
InnovAge Holding
―
Agilon Health
―
Options Prices
Currently, No data available
---